CAS NO: | 13551-87-6 |
包装 | 价格(元) |
1mg | 电议 |
5mg | 电议 |
10mg | 电议 |
50mg | 电议 |
Cas No. | 13551-87-6 |
别名 | 米索硝唑,NSC 261037,Ro 7-0582,SR 1354 |
化学名 | α-(methoxymethyl)-2-nitro-1H-imidazole-1-ethanol |
Canonical SMILES | OC(COC)CN1C=CN=C1[N+]([O-])=O |
分子式 | C7H11N3O4 |
分子量 | 201.2 |
溶解度 | ≤5mg/ml in ethanol;15mg/ml in DMSO;15mg/ml in dimethyl formamide |
储存条件 | Store at -20℃ |
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
产品描述 | Misonidazole (MISO), a hypoxic cell radiosensitizer, is selectively metabolized by hypoxic cells to reactive products that bind covalently to cellular constituents. The drug also possesses a substantial cytotoxic effect, independent of radiation, which is selectively expressed in hypoxic cells. Misonidazole may be cytotoxic to the normal hypoxic tissues in the human body, making this became a major concern in the clinical application of the drug. Misonidazole leads to strand breaks in cellular DNA and those cells which fail to survive also fail to repair these strand breaks. Misonidazole depletes intracellular glutathione and is more toxic in glutathione depleted cells. The depletion is time, temperature, drug concentration and cell line dependent. In vitro: In cultured CHO cells, pretreatment with 5 mM MISO for 2 hr exihibited the marginal toxicity [2]. In vivo: Pretreatment with misonidazole (MISO) enhanced the number of cross-links formed in a fibrosarcoma and in the spleen and gut of mice for periods up to 48 h following a single injection of melphalan (MEL). MISO pretreatment could result in a greater amount of binding of MEL to DNA at early times after injection. MISO may exert its affect by inhibiting the repair of cross-links or monoadducts at early times post-injection [3]. Clinical trials: Various dose schedules of misonidazole have proven to be tolerable, with a moderate incidence of nausea and vomiting and mild peripheral neuropathy, and a low incidence of more severe peripheral neuropathy or central neuropathy [4]. References: |